About
The United States remains a global leader in medical innovation, but the clinical trial and commercialization system is increasingly weighed down by inefficiencies that delay access to life-saving therapies.
Site activation alone can take many months—sometimes more than a year—due to redundant IRB reviews, slow contract negotiations, and fragmented regulatory processes. Even after activation, enrollment struggles persist, causing many trials to miss accrual goals or close prematurely. This is especially damaging for patients with aggressive or rare diseases who can’t afford to wait.
Compounding the challenge, the cost of running clinical trials in the U.S. is among the highest in the world. Administrative burdens, and inefficient site-level operations have made the system financially unsustainable.
Meanwhile, countries like China and others across Asia are streamlining timelines, modernizing regulations, and aggressively investing in clinical trial infrastructure—gaining ground as preferred regions for early- and late-phase trials. If the U.S. fails to modernize, we risk not only ceding global scientific leadership, but also limiting the availability of cutting-edge therapies to our own patients.
We must create better systems to move research to commercialization to compete in a changing competitive landscape globally. Origin was created to address this exact problem. By decentralizing research across a network of community, academic health systems, individual researchers and scientific leaders, and building infrastructure to accelerate trials where patients already receive care, we’re working to increase trial participation, lower costs, reduce timelines, and modernize the systems that push discoveries forward.
For more than 15 years, Origin has brought together leading research institutes and scientific professionals to accelerate access to the most promising medical advances for those in greatest need—and to develop and operate better pathways for scientific innovators to bring their breakthroughs to the world.
The Origin Model Focuses on 3 Overlapping Areas
1. A Next-Generation Decentralized Research and Clinical Trials Platform
A network of forward-thinking research centers and large integrated/community health systems has partnered with Origin to modernize clinical trials and drug development within their systems. Together, we are accelerating access to novel therapies and expanding the field to include broader patient populations and a new generation of researchers—connecting them to the most promising, life-saving treatments. Origin integrates highly specialized teams and capabilities directly into these partner systems, focused on scientific and clinical execution, administration and operations, legal and commercialization, and financial and strategic implementation. This dynamic, integrated model allows individual research programs to operate at a much higher level and outperform out-dated research and clinical trial models. This platform bridges the gap between academic centers, community health systems, drug developers, and individual investigators, significantly advancing research and clinical trials, ensuring the most promising therapies reach patients faster and more efficiently.
2. Partnering Directly With Individual Researchers and Scientific Talent in a Proprietary Research-to-Commercialization Platform
Origin is addressing a widening gap when science is too early for co-investors by working alongside investigators at their most critical stage . We are dedicated to providing financial and operational support for the most promising scientists at their most vulnerable stage—between discovery and investment by traditional capital markets or strategic investors. Without a fiduciary partner fully aligned with scientists and their missions—across institutions, organizations, and funding pathways—many of their most daring ideas may never reach the patients and families who need them most. Closing this critical gap benefits investigators, co-investors, research institutions, and biopharma alike—creating smarter, more effective pathways for great science and innovation to move from idea to impact.
Our mission is to help more talent and discoveries reach investors and strategic partners in stronger financial, scientific, and structural shape—giving them the best possible chance to move forward.